Full Text View
Tabular View
No Study Results Posted
Related Studies
Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
This study is currently recruiting participants.
Verified February 2013 by GlaxoSmithKline
Study NCT01160094   Information provided by GlaxoSmithKline

First Received on July 8, 2010.   Last Updated on April 11, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cancer
Interventions listed in this trial
Treatment
Additional drug interventions recognized in this trial
Capecitabine
Lapatinib
Trastuzumab
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services